Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Trial Profile

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tasadenoturev (Primary) ; Interferon gamma
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms TARGET-I
  • Sponsors DNAtrix
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 30 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top